Re-Expression of Fetal Igf2 as Epidriver and Target for Therapy in Hcc

Iris Martinez-Quetglas; Roser Pinyol; Daniel Dauch; Sara Torrecilla; Victoria Tovar; Agrin Moeini; Clara Alsinet; Silvana Bonilla; Anna Portela; Leonardo Rodríguez‐Carunchio; María A. Solé; A. Villanueva; Manel Esteller; Lars Zender; Josep M. Llovet

doi:10.1016/s0168-8278(16)01663-9

Related publications

Article2014

466 IGF2 drives IGF oncogenic signaling in HCC and emerges as a potential target for therapies

I.M. Quetglas, Roser Pinyol, Daniel Dauch, Anna Portela, Alberto Villanueva, Judit Peix, María Ángeles Moreno de la Higuera, Agrin Moeini, Jessica Zucman‐Rossi, Manel Esteller, Vincenzo Mazzaferro, Lars Zender, Josep M. Llovet

European Journal of Cancer

Article2015

P0265 : IGF2 is an oncogenic driver in HCC and emerges as a potential target for therapies

Iris Martinez-Quetglas, Roser Pinyol, Daniel Dauch, Anna Portela, Judit Peix, Mónica Higuera, Jessica Zucman‐Rossi, Manel Esteller, Vincenzo Mazzaferro, Lars Zender, Josep M. Llovet

Journal of Hepatology

Article2016

Abstract 3820: Epigenetic re-expression of fetal IGF2 as therapeutic target in hepatocellular carcinoma

Iris Martinez-Quetglas, Roser Pinyol, Daniel Dauch, Sara Torrecilla, Victoria Tovar, Agrin Moeini, Clara Alsinet, Anna Portela, Augusto Villanueva, Manel Esteller, Lars Zender, Josep M. Llovet

Cancer Research

Letter2003

HCC surveillance: Who is the target population?

Jordi Bruix, Josep M. Llovet

Hepatology

Article2001

VEGF and iNOS expression in human hepatocellular carcinoma (HCC)

Loreto Boix, Carolina Armengol, M Solé, Wladimiro Jiménez, Josep M. Llovet, J Rodés, Jordi Bruix